noticed the same thing. We already have ovarian preclinicals which were good but market opportunity was indifferent, but now adding cardio protect that turns the table. Still of the view FTO trial will be a separate showcase based on the 100+ review.
General Comments / Chat, page-7500
-
- There are more pages in this discussion • 4,384 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.59 |
Change
0.000(0.00%) |
Mkt cap ! $270.9M |
Open | High | Low | Value | Volume |
$1.61 | $1.62 | $1.55 | $189.9K | 121.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1316 | $1.58 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.59 | 34961 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1316 | 1.580 |
1 | 400 | 1.560 |
2 | 8157 | 1.550 |
1 | 6250 | 1.540 |
1 | 25000 | 1.530 |
Price($) | Vol. | No. |
---|---|---|
1.590 | 34961 | 1 |
1.595 | 3134 | 2 |
1.600 | 3000 | 1 |
1.650 | 17029 | 2 |
1.690 | 6570 | 3 |
Last trade - 16.10pm 14/10/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, Managing Director & CEO
Charles Armstrong
Managing Director & CEO
SPONSORED BY The Market Online